Measuring ROS in Cell Culture Samples:
A Mitochondrial Disease Drug Discovery
Case Study
Louise Young is a research fellow in the Strathclyde Institute of Pharmacy and Biomedical Sciences department at the University of Strathclyde. Louise and her team study mitochondria and how the dysfunction of mitochondria is involved in a range of diseases including Alzheimer’s disease and cancer.
The team collaborate with chemists to compile and test a range of compounds for their ability to decrease ROS output from stressed mitochondria. Their workflow includes an assay platform which features a range of Promega assays including: ROS-Glo™ H2O2 Assay, RealTime-Glo™ Annexin V Apoptosis and Necrosis Assay and CellTiter-Glo® 2.0 Cell Viability Assay.
In this case study, Louise discusses her work and specifically how ROS-Glo™ is an improvement on her previous assay, she discusses ROS-Glo’s fast turnaround time and how the no-wash protocol has improved reproducibility.
Several of the compounds tested have been shown to reduce the amount of ROS produced. Future work will focus on these compounds and their protein targets.
Download the PDF of the case study here >
